DDInter458 DDInter1725
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulfasalazine fell out of favor as the drug of choice for RA due to poorly designed clinical trials in 1950 but regained interest from the clinical community in the late 1970. Although sulfasalazine is only approved by the FDA for ulcerative colitis, research have shown that sulfasalazine is also beneficial for patients with Crohn's disease. Meta-analysis of 19 randomized controlled trials indicated that sulfasalazine is superior to placebo in inducing remission; however, with no supported evidence of mucosal healing, sulfasalazine is not FDA-recommmended for treatment of Crohn's disease.[A255597,A255602,A255607]
Cyclosporine {u} (Compound) treats {v} (Disease) rheumatoid arthritis
rheumatoid arthritis {u} (Disease) is treated by {v} (Compound) Sulfasalazine
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC7A11
SLC7A11 {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Cyclosporine {u} (Compound) downregulates {v} (Gene) ITGAE
ITGAE {u} (Gene) is downregulated by {v} (Compound) Sulfasalazine
Cyclosporine {u} (Compound) treats {v} (Disease) rheumatoid arthritis
rheumatoid arthritis {u} (Disease) resembles {v} (Disease) ankylosing spondylitis
ankylosing spondylitis {u} (Disease) is treated by {v} (Compound) Sulfasalazine
Cyclosporine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is regulated by {v} (Gene) IKBKB
IKBKB {u} (Gene) is bound by {v} (Compound) Sulfasalazine
Cyclosporine {u} (Compound) binds {v} (Gene) SLCO1B1
SLCO1B1 {u} (Gene) is bound by {v} (Compound) Digoxin
Digoxin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Cyclosporine {u} (Compound) binds {v} (Gene) ABCC2
ABCC2 {u} (Gene) regulates {v} (Gene) GDF15
GDF15 {u} (Gene) is downregulated by {v} (Compound) Sulfasalazine
Cyclosporine {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Vismodegib
Vismodegib {u} (Compound) resembles {v} (Compound) Sulfasalazine
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC7A11
SLC7A11 {u} (Gene) is upregulated by {v} (Disease) Crohn's disease
Crohn's disease {u} (Disease) is treated by {v} (Compound) Sulfasalazine
Cyclosporine (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is treated by Sulfasalazine (Compound)
Cyclosporine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Sulfasalazine (Compound)
Cyclosporine (Compound) upregulates SLC7A11 (Gene) and SLC7A11 (Gene) is bound by Sulfasalazine (Compound)
Cyclosporine (Compound) downregulates ITGAE (Gene) and ITGAE (Gene) is downregulated by Sulfasalazine (Compound)
Cyclosporine (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) resembles ankylosing spondylitis (Disease) and ankylosing spondylitis (Disease) is treated by Sulfasalazine (Compound)
Cyclosporine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is regulated by IKBKB (Gene) and IKBKB (Gene) is bound by Sulfasalazine (Compound)
Cyclosporine (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Digoxin (Compound) and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine
Cyclosporine (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) regulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Sulfasalazine (Compound)
Cyclosporine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Vismodegib (Compound) and Vismodegib (Compound) resembles Sulfasalazine (Compound)
Cyclosporine (Compound) upregulates SLC7A11 (Gene) and SLC7A11 (Gene) is upregulated by Crohn's disease (Disease) and Crohn's disease (Disease) is treated by Sulfasalazine (Compound)